Journal of Medicinal Chemistry · 2022 · 41 citations · 24 references
PharmacyImmunologyPharmacologyDrug DeliveryDrug DesignTargeted Drug DeliveryAntibody CharacterizationAntibody ConjugatesAntibody ConjugationAntibody-drug ConjugatesTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate LinkersAntibody-drug LinkersGlucocorticoid PharmacologyGlucocorticoid-mediated Immune ModulationPayload AnalysisPayload DeliveryTherapeutic Window Determination
Glucocorticoid receptor modulators (GRM) are the first-line treatment for many immune diseases, but unwanted side effects restrict chronic dosing. However, targeted delivery of a GRM payload via an immunology antibody-drug conjugate (iADC) may deliver significant efficacy at doses that do not lead to unwanted side effects. We initiated our α-TNF-GRM ADC project focusing on identifying the optimal payload and a linker that afforded stable attachment to both the payload and antibody, resulting in the identification of the synthetically accessible maleimide-Gly-Ala-Ala linker. DAR 4 purified ADCs were shown to be more efficacious in a mouse contact hypersensitivity model than the parent α-TNF antibody. Analysis of P1NP and corticosterone biomarkers showed there was a sufficient therapeutic window between efficacy and unwanted effects. In a chronic mouse arthritis model, α-TNF-GRM ADCs were more efficacious than both the parent α-TNF mAb and an isotype control bearing the same GRM payload.
24
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations